Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
fMRI study of NKTR-181 in recreational opioid users
NCT03802227Phase 1Terminated
- Sponsor
- Nektar Therapeutics
- Start
- Oct 2018
- Primary completion
- Dec 2019
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of loxicodegol in chronic pain (2 arms), sponsored by Nektar Therapeutics. Primary endpoint: Brain Activity Measured Via fMRI at 4 hours. Started Oct 2018; status: terminated.
02
Drugs
loxicodegol
03
Conditions
chronic pain
Beyond the preview
Go deeper on NCT03802227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03802227.